The price of Belcher Pharmaceuticals’ Acthar gel skyrocketed after having been granted orphan status by the Food and Drug Administration, and a city in Georgia is firing back in a new lawsuit that claims the drugmaker is keeping the price artificially high, according to media reports.
According to a STAT report, a 10-vial pack of the treatment for hypertrophic obstructive cardiomyopathy surged from about $1,300 to almost $10,000.
The city of Marietta in its lawsuit is accusing the company of “unjust enrichment,” the Associated Press reports.
To read the AP’s write up, click here.
Click here to read STAT’s report. (Paid subscription required)
